Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity

BackgroundContinuous ibrutinib administration is needed to maintain efficacy in patients with chronic lymphocytic leukemia (CLL) and, as such, long-term toxicity is a concern. The authors report the 5-year follow-up of patients with CLL who received treatment with ibrutinib with a focus on hypertension and cardiovascular toxicities. MethodsPatient characteristics were assessed, including blood pressure, cardiovascular disease, disease progression, and death. Univariate logistic regression analysis assessed the relation of patient characteristics and the development of new or worsened hypertension. The incidence of hypertensive outcomes was evaluated using competing risk. Survival was estimated using the Kaplan-Meier method. ResultsThree hundred patients with CLL who were treated with ibrutinib on clinical trials were included. The median patient age at study enrollment was 65 years (range, 29-83 years). Seventy percent of patients were men, and 88% were Caucasian. Sixty-nine percent of patients had hypertension at baseline, and 47% were on antihypertensive medication. Eighty-eight percent had relapsed or refractory CLL. New-onset and worsening hypertension were common, occurring in 68.5% and 38% of patients, respectively. Systolic blood pressure >= 160 mm Hg or diastolic blood pressure >= 100 mm Hg was observed in 16.9% of patients. Hypertension was reversible after ibrutinib discontinuation. Older age, male sex, tobacco use, and chronic kidney disease were associated with ibrutinib-related hypertension. Baseline hypertension was not associated with major adverse cardiovascular events in ibrutinib-treated patients nor with event-free or overall survival. ConclusionsHypertension is a common toxicity in patients with CLL who receive ibrutinib but is manageable in most patients. Other than chronic kidney disease, baseline cardiovascular disease did not affect ibrutinib-related hypertension nor was hypertension associated with major adverse cardiovascular events or survival. Plain Language Summary Ibrutinib is an effective treatment for patients with chronic lymphocytic leukemia.Ibrutinib is a well tolerated therapy, however hypertension can develop or worsen in patients receiving ibrutiniband other cardiovascular events are significant challenges to the use of this drug.This may be particularly true in patients with heart disease.Short-term side effects may worsen heart disease, but the long-term impact is unknown.The long-term results of ibrutinib on heart disease and hypertension are described.

Automated summary

This study reports the 5-year follow-up results of patients with CLL who received treatment with ibrutinib, focusing on hypertension and cardiovascular toxicities. The findings showed that although hypertension is a common side effect, it is manageable in most patients, and baseline cardiovascular disease does not affect ibrutinib-related hypertension nor is hypertension associated with major adverse cardiovascular events or survival.